COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB VERSUS CHEMOTERAPY FOR FIRST LINE TREATMENT OF NONSMALL CELL LUNG CANCER ALK plus , FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

被引：0
|
作者：
Ferreira, P. [1 ]
Senna, T. [1 ]
Sebastiao, M. [1 ]
Alexandre, R. F. [1 ]
Almeida, P. [1 ]
机构：
[1] Pfizer, Sao Paulo, SP, Brazil
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE52
引用
收藏
页码：S68 / S69
页数：2
相关论文
共 50 条
  • [11] First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China
    Li Ling-Yu
    Wang Hong
    Chen Xiao
    Li Wen-Qian
    Cui Jiu-Wei
    中华医学杂志英文版, 2019, 132 (23) : 2790 - 2794
  • [12] First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China
    Li, Ling-Yu
    Wang, Hong
    Chen, Xiao
    Li, Wen-Qian
    Cui, Jiu-Wei
    CHINESE MEDICAL JOURNAL, 2019, 132 (23) : 2790 - 2794
  • [13] COST-EFFECTIVENESS ANALYSIS OF TRANSTHYRETIN-ASSOCIATED AMYLOID CARDIOMYOPATHY FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
    Sebastiao, M.
    Ferreira, P.
    Senna, T.
    Alexandre, R. F.
    Almeida, P.
    VALUE IN HEALTH, 2023, 26 (06) : S156 - S156
  • [14] Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC - A Real World Study
    Huang, M.
    Tian, Y.
    He, M.
    Ren, L.
    Gong, Y.
    Peng, F.
    Wang, Y.
    Ding, Z.
    Wang, J.
    Zhu, J.
    Xu, Y.
    Liu, Y.
    Li, L.
    Lu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S475 - S475
  • [15] COST-MINIMIZATION OF LORLATINIB VERSUS ALECTINIB FOR FIRST LINE TREATMENT FOR TREATMENT OF ALKPOSITIVE NON-SMALL-CELL LUNG CANCER FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Senna, T.
    Alexandre, R. F.
    Almeida, P.
    Sebastiao, M.
    Ferreira, P.
    VALUE IN HEALTH, 2023, 26 (06) : S87 - S87
  • [16] Cost-effectiveness analysis of pemetrexed and gemcitabine treatment for advanced nonsmall cell lung cancer in Turkey
    Balcik, Pinar Yalcin
    Sahin, Bayram
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2016, 46 (01) : 152 - 158
  • [17] cost-effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer
    Zhang, Huahua
    Zheng, Xiaochun
    Zhang, Yandong
    Wang, Jiangfeng
    FUTURE ONCOLOGY, 2024, : 2661 - 2670
  • [18] Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX plus bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis
    Peria, F. M.
    Ungari, A. Q.
    Dos Santos, F. N.
    Lins-Almeida, T.
    Nunes, A. A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [19] COST-EFFECTIVENESS OF CRIZOTINIB, CERITINIB, AND ALECTINIB AS FIRST-LINE TREATMENTS FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) METASTATIC NON-SMALL CELL LUNG CANCER
    Xuan, S.
    Ma, J.
    VALUE IN HEALTH, 2018, 21 : S32 - S33
  • [20] Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective
    Lian, Dai
    Yang, Yi
    Gan, Yuling
    Xiao, Dunming
    Xiang, Yuliang
    Jiang, Shan
    Gu, Yuanyuan
    Chen, Yingyao
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, : 587 - 596
12345